CinCor Pharma's baxdrostat has shown statistically significant reductions in systolic blood pressure in patients with hard-to-control hypertension, according to full results from the BaxHTN Phase III trial announced on August 30, 2025. DelveInsight examines the market impact and evolving competitive landscape in the hypertension treatment sector.   Hypertension Market Insights,...